Free Newsletter
DNA databank marries bio samples and EMRs
Use of DNA variations as an indicator of patient response to medicines is one study underway that taps the newly available Vanderbilt University DNA databank, BioVU. The databank--currently available only to Vanderbilt researchers and collaborators--contains de-identified biological samples from 75,000 individuals collected since 2007 and has linked them the matching electronic medical records. Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: